Study Summary
To evaluate the safety and effectiveness of cell therapy using herinCAR-PD1 cells to treat advanced cancer. Individuals greater than or equal to 18 years of age and less than or equal to 70 years of age who have been diagnosed with relapsed or refractory cancer that has not responded to or has relapsed after standard treatment.
Want to learn more about this trial?
Request More InfoInterventions
HerinCAR-PD1 cellsBIOLOGICAL
herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Ningbo No.5 Hospital (Ningbo Cancer Hospital) | Ningbo | Zhejiang | China |